StockUS listing USHCWBNASDAQHealthcareCapital Destroyer

HCW Biologics Inc(HCWB) Stock Analysis | Healthcare

USD --+0.00%
Reward34Low
Risk92High
75%Data
Thin -83% profit margin · Revenue growing 1970% YoY
USD —+0.00 (+0.00%) Previous close · NASDAQ
Market cap 2.35M
Reward Ratingⓘ34 Low reward assessment · 75% data coverage
Bottom 5% of stocksView factors
Risk Ratingⓘ92 High risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on HCWB to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is HCW Biologics Inc?

, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and diseases in the United States.

AI Brief Pro

The brief on HCW Biologics Inc

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is HCW Biologics Inc?

, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and diseases in the United States. Its lead products include HCW11-018b, a novel, tetra-valent T-Cell engager; HCW11-040, a multifunctional fusion molecule that is a combination of cytokines and pembrolizumab; and HCW9302, injectable and interleukin 2 (IL-2) fusion protein complex, which is in clinical trial in patients with alopecia areata diseases. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 2.35M.

Financial Highlights

Investment Breakdown

Growth
Revenue and earnings growing steadily, indicating improving operating performance.
Profitability
Thin or inconsistent margins weigh on earnings quality.
Risk
Elevated volatility implies higher downside and expectation risk.
Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Low (34)
Company Information
SectorHealthcare
IndustryBiotechnology
Beta2.273
Insider Activity
12M windowBullish
Shares soldShares bought
0-3months
0
0
3-6months
0
338,682 shares
$100k
6-9months
0
3306,050 shares
$430k
9-12months
0
0